Immunogenicity and safety of recombinant tetravalent dengue vaccine (CYD-TDV) in individuals aged 2-45 y: Phase II randomized controlled trial in Singapore.
This was a multicenter, blinded, Phase II study (NCT00880893) conducted in Singapore. The primary objectives were to evaluate the safety of a tetravalent dengue vaccine (TDV) comprising four recombinant, live, attenuated viruses (CYD-TDV) and the dengue virus serotype-specific antibody responses before and 28 d after each vaccination. Participants were randomized 3:1 to receive three doses of CYD-TDV or a control vaccine at 0, 6 and 12 mo. Control vaccine was placebo for the first dose (all ages) and for subsequent doses, licensed hepatitis-A for children (aged 2-11 y) or influenza vaccine for adolescents (12-17 y) and adults (18-45 y). Between April and October 2009, 317 children, 187 adolescents and 696 adults were enrolled. In all age groups, reactogenicity was higher after the first injection of CYD-TDV than after placebo control. Reactogenicity after subsequent CYD-TDV doses was no higher than after the first dose, and tended to be lower or similar to that seen after active control vaccination. Seropositivity rates and geometric mean neutralizing antibody titers (GMTs; 1/dil) against all four dengue virus serotypes increased in all age groups after each of the three CYD-TDV doses. Post-dose 3, 66.5% of all participants were seropositive to all four serotypes, and 87.2% were seropositive to ≥ 3 serotypes; GMTs for all participants ranged from 43.0 against dengue virus serotype 1 to 100 against dengue virus serotype 4. GMTs were higher in children than in adolescents. These results support the continued development of CYD-TDV for the prevention of dengue disease.
Tan Tock Seng Hospital; Singapore.
Yee Sin
YS
Leo
Anneliese
A
Wilder-Smith
Sophia
S
Archuleta
Lynette P
LP
Shek
Chia-Yin
CY
Chong
Hoe Nam
HN
Leong
Chian Yong
CY
Low
May-Lin Helen
ML
Oh
Alain
A
Bouckenooghe
T Anh
TA
Wartel
Denis
D
Crevat
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003715:Dengue / Q000276:immunology / Q000517:prevention & control; D053059:Dengue Vaccines / Q000009:adverse effects* / Q000276:immunology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012846:Singapore; D055815:Young Adult
D053059:Dengue Vaccines